Samia Arifi

Publications

• Research Article   
  Paclitaxel as first or second line treatment for Kaposi's sarcomas: A retrospective study from the north-east of Morocco
  Author(s): Mohammed Ismaili*, Khaoula Alaoui Ismaili, Imane Stitou, Oumaima Siyouri, Mohammed Ait Raisse, Nawal Hammas, Nawfel Mellas and Samia Arifi
  
  Introduction: Paclitaxel has recently been approved for AIDS-related Kaposi's Sarcoma (KS) and there is much interest also in HIV-negative KS. In our study we aimed to report the activity and safety data of paclitaxel from a cohort of patients from the north east of Morocco. Patients and Methods: A retrospective analysis of our departmental database from January 2010 to December 2018 was performed. Histologically proven KS cases were recorded. Patients, tumour characteristics, treatment and outcome were analysed. Results: 16 patients were identified. KS represents 0,13% of all oncology admissions. The mean age at diagnosis was 67 years (+/-17,8) with a sex ration of 3:1. Among these patients 14 had a classic KS, and 2 were HIV-positive. The most common primary site was the lower limbs (50%). The involvement of lymph nodes, mucosa, and/or visceral organs has bee.. Read More»
  

  Abstract HTML PDF